Insight: How new cancer drugs can skip randomized trials
Back in 2006 when doctors started testing a melanoma treatment on chemotherapy patients with the hopes of shrinking tumors – they were used to facing slim odds. But now, a new drug called Zelboraf that targets specific mutations in cancer cells, is helping them beat those odds by showing signs of significant tumor shrinkage. These Zelboraf research tests, that fine-tune treatments to the genetic profile of patients, is indeed fueling a rethink over how new cancer drugs are tested…
To read more, click here.
Image source
